What's Happening?
Innocan Pharma Corporation has closed an additional debenture offering to its largest shareholder, Tamar Innovest Ltd., for gross proceeds of US $200,000. This follows a previous debenture offering of $450,000. The debenture bears an interest rate of 10%
per annum and matures within 12 months or upon completion of a proposed public offering in the U.S. The transaction is classified as a related party transaction under Multilateral Instrument 61-101.
Why It's Important?
The closing of the additional debenture provides Innocan Pharma with necessary capital to support its operations and strategic initiatives. The involvement of Tamar Innovest, a major shareholder, indicates confidence in Innocan's business prospects. The funds raised will likely be used to advance Innocan's pharmaceutical and wellness projects, particularly in the development of CBD-loaded drug delivery platforms and health-oriented products.
What's Next?
Innocan Pharma is expected to proceed with its proposed public offering in the U.S., which could provide further capital for expansion and development. The company will continue to focus on its growth strategy, leveraging its innovative drug delivery technologies and expanding its product portfolio. Investors will be keen to see how Innocan utilizes the funds to enhance its market position and drive future growth.
